NEO100 and High-Grade Meningioma

NCT05023018 | Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: NEO100-02
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 3

Brief Summary

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.

Conditions

Residual, Progressive or Recurrent Grade II or III Meningioma

Keywords

Residual, Progressive or Recurrent Grade II or III Meningioma

Outcome Measures

Primary Outcomes (1)

• Progression free survival as six months (PFS6).

  Progression free survival

  6 months

Secondary Outcomes (3)

• Objective Tumor response to NEO100 as determined by RANO criteria

  6 months

• Overall survival

  12 months

• Perillic acid measurement

  30 days

Study Arms (1)

Patients with high-grade meningioma

EXPERIMENTAL

30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma

Drug: NEO100

Interventions

NEO100 DRUG

NEO100 is a purified form of perillyl alcohol.

Patients with high-grade meningioma

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient must:
• Have histologically confirmed WHO Grade II or III meningioma that is residual, progressive or recurrent following at least minimally safe resection and radiation therapy. Metastatic meningiomas are allowed.
• Residual disease is defined as residual measurable disease (without a requirement for progression). Residual measurable disease is defined by bidimensionally measurable lesions with clearly defined margins by MRI scan(s) with a minimum diameter of 10mm in both dimensions.
• Progressive disease is defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area). The change must occur between scans separated by no more than 24 months.
• Recurrent disease is defined as new evidence of measurable disease following complete resection (10mm in both dimensions).
• Be on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
• Participants must have failed maximal safe resection and radiation therapy.
• There is no limit on the number of prior surgeries, radiation therapy, radiosurgery treatments or systemically administered therapeutic agents, however, these treatment(s) must comply with the following:
• There is no limit on the number of prior therapies.
• Prior medical therapy is allowed but is not required.
• No chemotherapy, other investigational agents within 14 days of study treatment.
• For prior systemic agents, participants must be at least 4 weeks (or 5 half-lives, whichever is shorter) from other prior cytotoxic chemotherapy (6 weeks from nitrosoureas/alkylating agents) or biologic therapies.
• No other concurrent receipt of investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study.
• Patients may have been treated with standard external beam radiation or radiosurgery in any combination; however an interval of ≥12 weeks (84 days) must have elapsed from the completion of the radiation therapy to the initiation of study therapy unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line). In addition, there must be subsequent evidence of tumor progression after completion of radiation therapy;
• An interval of ≥ 28 days and full recovery (no ongoing safety issues) from surgical resection is required;

You may not qualify if:

• Patients who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days (or 5 half-lives, whichever is shorter) of study treatment.
• Patient has completed chemo-radiation within the last 84 days prior to the first administration of study drug, unless new contrast enhancement is outside of radiation field, or there is tissue proven recurrence or progression.
• Patient has had surgery within seven days prior to the date of informed consent.
• Patient has had cytotoxic chemotherapy within 4 weeks (or 5 half-lives, whichever is shorter), nitrosoureas/alkylating agents within 6 weeks or biologic therapies.
• Prior treatment with interstitial brachytherapy within 6 months of start of study therapy.
• Current or planned participation in a clinical trial of an investigational agent or using an investigational medical device.
• The patient's disease is primarily localized to the brainstem or spinal cord;
• Patient has not recovered from adverse events due to chemotherapy, immunotherapy, or radiation therapy.
• Patient has had prior treatment with perillyl alcohol.
• Patient has a history of allergic reactions attributed to perillyl alcohol.
• Patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Patient must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
• Patient has a history of new diagnosis or treatment of cancer other than high-grade meningioma within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
• Leptomeningeal involvement of the patient's tumor.

Sponsors & Collaborators

• Neonc Technologies, Inc.: lead

Study Sites (3)

University of Southern California

Los Angeles, California, 90033, United States

RECRUITING

Saint John Cancer Institute

Santa Monica, California, 90404, United States

RECRUITING

Baylor Scott and White

Dallas, Texas, 75246, United States

RECRUITING

MeSH Terms

Conditions

Lymphoma, Follicular

Interventions

perillyl alcohol

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Tom Chen, MD, PhD

  NeOnc Technologies

  STUDY CHAIR

• Josh Neman

  NeOnc Technologies Holdings, Inc.

  STUDY DIRECTOR

Central Study Contacts

Chris Beardmore

CONTACT

224 218 2408; chris@anovaevidence.com

Chloe Richmond

CONTACT

224 218 2408; chloe@anovaevidence.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This multi-site, Phase 2 clinical trial is an open label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed residual, progressive or recurrent high-grade meningioma. There will be up to 30 patients enrolled into the study to enroll 28 evaluable patients. NEO100 will be self-administered four times daily for a 28-day treatment cycle until disease progression, death or patient withdraw for any reason, whichever occurs first.

Study Record Dates

• First Submitted: August 20, 2021
• First Posted: August 26, 2021
• Study Start: July 1, 2022
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): June 30, 2027
• Last Updated: March 2, 2026

Record last verified: 2026-01

Locations

US (3)